Read Full Important Safety Information

For U.S. Healthcare Professionals Only

Helpful Documents

Get the resources you need

Download these helpful resources to guide you in prescribing Adlyxin.

Physician Instructions for Use
Dosing Guide
Adlyxin Co-pay FAQs

Pay as little as $0*

if enrolled in the Sanofi Rx Savings program and taking select Sanofi diabetes products.Pay as little as $15 if new to the program.

See Program Restrictions below *

View Savings Program

Get the help your patients need

Download the PDFs below to get information and support on the management of blood sugar, as well as tips on diet and exercise.

Blood Sugar Tracker
Tools and Support to Help Manage Your Diabetes
Sanofi Patient Connection™

Indications and Limitations of Use for Adlyxin (lixisenatide) injection

Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:

  • Has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  • Not for treatment of type 1 diabetes or diabetic ketoacidosis.
  • Has not been studied in combination with short acting insulin.
  • Has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis.

Important Safety Information for Adlyxin (lixisenatide) injection

Contraindications

  • Adlyxin is contraindicated in patients with known hypersensitivity to lixisenatide or to any component of Adlyxin. Hypersensitivity reactions including anaphylaxis have occurred with Adlyxin.

Warnings and Precautions

  • Anaphylaxis and Serious Hypersensitivity Reactions: In clinical trials of Adlyxin there have been cases of anaphylaxis determined to be related to Adlyxin. Other serious hypersensitivity reactions including angioedema also occurred. If a hypersensitivity reaction occurs, patients must stop taking Adlyxin and promptly seek medical attention. Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis.
  • Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists based on spontaneous postmarketing reports. In clinical trials of Adlyxin, there were cases of pancreatitis among some Adlyxin treated patients. After initiation of Adlyxin, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, Adlyxin should promptly be discontinued and appropriate management should be initiated. If pancreatitis is confirmed, do not restart Adlyxin.
  • Never Share an Adlyxin Pen Between Patients, even if the needle is changed: Pen sharing poses a risk for transmission of blood-borne pathogens.
  • Hypoglycemia with Concomitant Use of Sulfonylurea or Basal Insulin: Patients receiving Adlyxin in combination with basal insulin or a sulfonylurea have an increased risk of hypoglycemia. Reduction of the dose of the sulfonylurea or basal insulin may be necessary.
  • Acute Kidney Failure: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1 receptor agonists. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Adlyxin in patients with renal impairment reporting severe gastrointestinal reactions. Adlyxin is not recommended in patients with end stage renal disease.
  • Immunogenicity: Patients may develop antibodies to lixisenatide following treatment with Adlyxin. A higher incidence of allergic reactions and injection site reactions occurred in antibody positive patients. If there is worsening glycemic control or failure to achieve targeted glycemic control, significant injection site reactions, or allergic reactions then alternative antidiabetic therapy should be considered.
  • Macrovascular Outcomes: Clinical studies have not shown macrovascular risk reduction with Adlyxin or any other antidiabetic drug.

Most Common Adverse Reactions (≥5%)
The most common adverse reactions associated with Adlyxin include nausea, vomiting, headache, diarrhea, dizziness, and hypoglycemia.

Drug Interactions
Adlyxin delays gastric emptying, which may reduce the rate of absorption of orally administered medications. Use caution when coadministering oral medications that have a narrow therapeutic ratio or that require careful clinical monitoring. These medications should be adequately monitored when concomitantly administered with Adlyxin. If such medications are to be administered with food, patients should be advised to take them with a meal or snack when Adlyxin is not administered.

Oral medications dependent on threshold concentrations for efficacy, such as antibiotics, or medications for which a delay in effect is undesirable, such as acetaminophen, should be administered at least 1 hour before Adlyxin injection.

Patients taking oral contraceptives should be advised to take them at least 1 hour before Adlyxin administration or at least 11 hours after the dose of Adlyxin.

Use in Specific Populations

  • Pregnancy and Nursing Women: The limited available data with lixisenatide in pregnant women are not sufficient to inform a drug-associated risk of major birth defects and miscarriage. Adlyxin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. There is no information regarding the presence of Adlyxin in human milk, the effects on the breastfed infant, or the effects on milk production.
  • Pediatric Use: Safety and effectiveness of Adlyxin have not been established in pediatric patients below 18 years of age.

Click here for Full Prescribing Information for Adlyxin.
Click here for Sharps Medical Waste Disposal.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610.

The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

*

*Co-Pay Program
Eligibility Restrictions:
This offer is for US residents over the age of 18 with commercial/private insurance and is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, or TRICARE, or similar federal or state programs including any state pharmaceutical assistance programs. Should you begin receiving prescription benefits from any federal, state or government funded program at any time, you will no longer be able to participate in this program. Important to note that if you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Also, if you have a Federal Employee Health Benefits (FEHB) plan with Commercial or private insurance, you may be qualified to receive and use this savings card. Void where prohibited by law.

Program Terms:
Patients enrolled in the Sanofi Rx Savings Program and currently using Toujeo ®(insulin glargine injection) 300 Units/mL or Lantus ®(insulin glargine injection) 100 Units/mL have a $0 copay per prescription for Adlyxin for 12 months. All other eligible patients have a $15 copay per prescription for 12 consecutive months. This offer will cover a copay balance up to a maximum of $700 off each Adlyxin prescription for the duration of the program. Savings may vary depending on individual out-of-pocket costs. This offer only applies to prescriptions requiring a copay and cannot be applied to prescriptions being paid in cash. Sanofi reserves the right to rescind, revoke, or amend the program at any time without notice.

Back to the top ▲

© 2019 sanofi‐aventis US LLC. All rights reserved.

Legal Disclaimer | Privacy Policy | Contact SANOFI

This site is intended for use by US Healthcare Professionals only.

SAUS.ADL.19.01.0294c Last Updated: January 2019

Important Safety Information for Adlyxin (lixisenatide) injection

Contraindications

  • Adlyxin is contraindicated in patients with known hypersensitivity to lixisenatide or to any component of Adlyxin. Hypersensitivity reactions including anaphylaxis have occurred with Adlyxin.

Warnings and Precautions

  • Anaphylaxis and Serious Hypersensitivity Reactions: In clinical trials of Adlyxin there have been cases of anaphylaxis determined to be related to